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A BS TR AC T 
BACKGROUND
The interferon-free combination of the protease inhibitor ABT-450 with ritonavir 
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the non-
nucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has 
shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 
infection. In this phase 3 trial, we evaluated this regimen in previously untreated 
patients with HCV genotype 1 infection and no cirrhosis.
METHODS
In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 
previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an 
active regimen consisting of a single-tablet coformulation of ABT-450/r–ombitasvir 
(at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of om bit-
asvir), and dasabuvir (250 mg twice daily) with ribavirin (in doses determined accord-
ing to body weight) (group A) or matching placebos (group B). The patients received 
the study treatment during a 12-week double-blind period. The primary end point was 
sustained virologic response at 12 weeks after the end of treatment. The primary 
analysis compared the response rate in group A with the response rate (78%) in a 
historical control group of previously untreated patients without cirrhosis who re-
ceived telaprevir with peginterferon and ribavirin. Adverse events occurring during 
the double-blind period were compared between group A and group B.
RESULTS
A total of 631 patients received at least one dose of the study drugs. The rate of sus-
tained virologic response in group A was 96.2% (95% confidence interval, 94.5 to 
97.9), which was superior to the historical control rate. Virologic failure during 
treatment and relapse after treatment occurred in 0.2% and 1.5%, respectively, of 
the patients in group A. The response rates in group A were 95.3% among patients 
with HCV genotype 1a infection and 98.0% among those with HCV genotype 1b 
infection. The rate of discontinuation due to adverse events was 0.6% in each study 
group. Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significant-
ly more patients in group A than in group B (P<0.05 for all comparisons). Reductions 
in the hemoglobin level were all of grade 1 or 2; reductions of grade 1 and 2 oc-
curred in 47.5% and 5.8%, respectively, of the patients in group A, whereas grade 1 
reductions occurred in 2.5% of the patients in group B.
CONCLUSIONS
In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 
12-week multitargeted regimen of ABT-450/r–ombitasvir and dasabuvir with ribavi-
rin was highly effective and was associated with a low rate of treatment discontinu-
ation. (Funded by AbbVie; SAPPHIRE-I ClinicalTrials.gov number, NCT01716585.)
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A pproximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 
people die of HCV-related liver disease each year.1,2 
Until recently, the standard of care for chronic 
HCV genotype 1 infection was a first-generation 
protease inhibitor, telaprevir or boceprevir, with 
peginterferon and ribavirin; this therapy resulted 
in rates of sustained virologic response of 67 to 
75% among previously untreated patients.3,4 The 
new standard of care is peginterferon and ribavirin 
combined with either the nucleotide nonstruc-
tural (NS) 5B polymerase inhibitor sofosbuvir or 
the protease inhibitor simeprevir.5 Peginterferon-
based treatment is associated with clinically sig-
nificant systemic events, including influenza-like 
symptoms and depression. Variables including pa-
tients’ age, race, HCV genotype, IL28B genotype, 
HCV viral load at baseline, and degree of liver 
fibrosis have been shown to affect the response 
to peginterferon-based therapy and other thera-
pies in development.3,4,6-9
ABT-450 is an HCV NS3/4A protease inhibitor 
with nanomolar potency in vitro. ABT-450 is ad-
ministered with low-dose ritonavir, an inhibitor 
of the cytochrome P-450 enzyme CYP3A4. As a 
pharmacologic enhancer of ABT-450, ritonavir 
facilitates once-daily dosing, and administra-
tion of ABT-450 with ritonavir (ABT-450/r) re-
sults in higher drug exposures than adminis-
tration of ABT-450 alone.10 Ombitasvir (also 
known as ABT-267) is an HCV NS5A inhibitor 
with picomolar potency in vitro. Dasabuvir (also 
known as ABT-333) is a nonnucleoside NS5B 
polymerase inhibitor with nanomolar potency 
in vitro.
In a phase 2b trial involving previously un-
treated patients with HCV genotype 1 infection, 
96% of the patients who received ABT-450/r, 
ombitasvir, dasabuvir, and ribavirin for 12 weeks 
had a sustained virologic response at 24 weeks 
after the end of treatment,
11 suggesting that a 
multitargeted approach may maximize the re-
sponse rate, such that most patients would have 
a sustained virologic response without the devel-
opment of drug resistance. Here we report the 
results of the phase 3, international, multicenter, 
randomized, double-blind, placebo-controlled 
SAPPHIRE-I trial evaluating the safety and effi-
cacy of 12 weeks of an all-oral regimen of ABT-
450/r–ombitasvir and dasabuvir with ribavirin 
in previously untreated patients with HCV geno-
type 1 infection and no cirrhosis.
ME THODS
PATIENTS
Patients were screened from November 2012 
through May 2013 at 79 sites in North America, 
Europe, and Australia. Eligible patients were 
adults, 18 to 70 years of age, with chronic HCV 
genotype 1 infection, no cirrhosis, and a plasma 
HCV RNA level of more than 10,000 IU per milli-
liter, who had never received antiviral treatment 
for HCV infection. Patients were excluded if they 
had a positive test for hepatitis B surface antigen 
or anti–human immunodeficiency virus antibody 
during screening. Details of the eligibility criteria 
are provided in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
STUDY DESIGN
Patients were randomly assigned, in a 3:1 ratio, 
to active treatment (group A) or placebo (group B) 
(Fig. 1). Randomization was stratified according 
to HCV genotype (1a vs. non-1a) and IL28B geno-
type (CC vs. non-CC). During the double-blind 
period, patients in group A received 12 weeks of 
treatment with oral coformulated ABT-450/r–
ombitasvir (at a once-daily dose of 150 mg of 
ABT-450, 100 mg of ritonavir, and 25 mg of om-
bitasvir) and dasabuvir (at a dose of 250 mg twice 
daily) with ribavirin, administered twice daily in a 
dose that was determined according to body weight 
(1000 mg daily if the body weight was <75 kg and 
1200 mg daily if the body weight was ≥75 kg). 
Patients in group B received matching placebos 
during the double-blind period. After the double-
blind period, patients in group B received the ac-
tive regimen as open-label therapy for 12 weeks.
The investigators, patients, and sponsor were 
unaware of the treatment assignments during 
the double-blind period. To prevent implicit un-
blinding, laboratory results for HCV RNA, hemo-
globin, hematocrit, alanine aminotransferase, 
aspartate aminotransferase, and bilirubin (indirect 
and total) levels were concealed from these parties. 
Details are provided in the Supplementary Appen-
dix. The study is ongoing, and all the patients 
will be followed for 48 weeks after the end of 
active treatment. Efficacy results in group A 
through post-treatment week 12 and safety data 
for both study groups are presented.
STUDY OVERSIGHT
All the patients provided written informed con-
sent. The study was conducted in accordance 
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with the International Conference on Harmonisa-
tion guidelines, applicable regulations, and the 
principles of the Declaration of Helsinki. The 
study protocol was approved by the independent 
ethics committee or institutional review board at 
each study site. The study was designed jointly by 
the study investigators and the sponsor (AbbVie). 
The investigators gathered the data, and the 
sponsor conducted the data analyses. All the au-
thors had full access to the data and signed con-
fidentiality agreements with the sponsor regard-
ing the data. The first draft of the manuscript 
was written by a medical writer who is an em-
ployee of the sponsor, with input from all the 
authors. All the authors reviewed and provided 
feedback on all subsequent versions of the manu-
script and made the decision to submit the man-
uscript for publication. All the authors vouch for 
the completeness and accuracy of the data and 
analyses presented and affirm that the study was 
conducted and reported with fidelity to the pro-
tocol (available at NEJM.org).
EFFICACY ASSESSMENTS
A central laboratory determined the HCV RNA 
level with the use of the COBAS TaqMan real-time 
reverse-transcriptase–polymerase-chain-reaction 
assay, version 2.0 (Roche). The lower limits of de-
tection and quantification were 15 IU per milli-
liter and 25 IU per milliliter, respectively. Details 
regarding the collection of plasma samples, the 
criteria for virologic failure, and resistance testing 
are provided in the Supplementary Appendix.
SAFETY ASSESSMENTS
Adverse events were assessed at each study visit. 
The investigator at each site classified events as 
mild, moderate, or severe. Data on all adverse 
events were collected from the start of study-
drug administration until 30 days after receipt of 
the last dose. Data on serious adverse events were 
collected throughout the entire study period. 
Here we report data on adverse events and serious 
adverse events occurring during the double-blind 
period and the 30-day period after the last dose 
of active study drugs was administered. Clinical 
laboratory testing was performed at visits during 
the double-blind treatment period and at weeks 4 
and 48 after the end of the treatment period.
EFFICACY END POINTS
The primary efficacy end point was sustained 
virologic response (HCV RNA level <25 IU per 
milliliter) at 12 weeks after the end of treatment. 
Secondary efficacy end points included normal-
ization of the alanine aminotransferase level, 
sustained virologic response at post-treatment 
week 12 according to HCV genotype (1a or 1b), 
virologic failure during treatment, and post-
treatment relapse. The primary analysis was per-
formed after all the patients in group A reached 
post-treatment week 12 and all those in group B 
reached week 12 of open-label treatment (Fig. 1). 
Primary analysis data are reported.
Normalization of the alanine aminotransfer-
ase level was defined as a final level that was no 
more than the upper limit of the normal range 
during the double-blind treatment period in pa-
tients whose baseline level had been higher than 
the upper limit of the normal range. Patients 
were considered to have virologic failure during 
treatment if they had a confirmed HCV RNA 
level of 25 IU per milliliter or more after the 
HCV RNA level had been lower than 25 IU per 
milliliter during treatment, if they had a con-
firmed increase in the HCV RNA level of more 
than 1 log10 IU per milliliter above the nadir 
observed during treatment, or if all the HCV 
RNA values during the treatment with the study 
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Figure 1. SAPPHIRE-I Study Design.
During the 12-week double-blind period, patients received either ABT-450 
with ritonavir (ABT-450/r)–ombitasvir and dasabuvir with ribavirin (group A) 
or matching placebos (group B). Patients receiving placebo were treated 
with the active regimen for 12 weeks in an open-label fashion at the conclu-
sion of the double-blind period. The dashed vertical line indicates the time 
point at which the primary analysis, which compared the rate of sustained 
virologic response at 12 weeks after the end of therapy in group A with the 
rate in a historical control group, was performed. The study is ongoing, and 
all patients who received the active regimen will be followed through post-
treatment week 48.
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drug administered for at least 6 weeks were 25 IU 
per milliliter or more. Virologic relapse was de-
fined as a confirmed HCV RNA level of 25 IU per 
milliliter or more between the final treatment 
visit and 12 weeks after receipt of the last dose 
of study drug among patients who completed 
treatment (duration of treatment, ≥77 days), who 
had an HCV RNA level that was lower than 25 IU 
per milliliter at the final treatment visit during 
the double-blind period, and who had HCV RNA 
data available after treatment.
STATISTICAL ANALYSIS
Analyses were performed in the modified inten-
tion-to-treat population, which included all the 
patients who underwent randomization and re-
ceived at least one dose of the study drug during 
the double-blind period. The primary efficacy 
analyses assessed noninferiority and superiority 
with respect to the rate of sustained virologic re-
sponse at post-treatment week 12 associated with 
the active regimen (ABT-450/r–ombitasvir and 
dasabuvir with ribavirin) by comparing it with a 
calculated historical control rate of 78% (95% 
confidence interval [CI], 75 to 80). This control 
rate was based on response rates among previ-
ously untreated patients without cirrhosis who 
received telaprevir and peginterferon–ribavirin.12
To establish that the rate of sustained viro-
logic response at post-treatment week 12 associ-
ated with the active regimen was noninferior to 
the historical control rate, the lower boundary of 
the 95% confidence interval for the rate of sus-
tained virologic response at post-treatment week 
12 in group A had to exceed the upper boundary 
of the 95% confidence interval for the control 
rate minus 10.5 percentage points (70%). To es-
tablish that the rate of sustained virologic re-
sponse at post-treatment week 12 associated with 
the active regimen was superior to the historical 
control rate, the lower boundary of the 95% 
confidence interval for the rate in group A had 
to exceed the upper boundary of the confidence 
interval for the historical rate (80%).
The two-sided 95% confidence intervals were 
calculated with the use of the normal approxi-
mation to the binomial distribution. We calcu-
lated that a sample of 600 patients (450 patients 
in group A) would provide the study with more 
than 90% power to show noninferiority and su-
periority of the active regimen, assuming a rate 
of sustained virologic response at post-treatment 
week 12 of 92%.
Secondary analyses assessed whether the rates 
of sustained virologic response at post-treatment 
week 12 in HCV genotype 1a–infected and HCV 
genotype 1b–infected subgroups of group A were 
superior to calculated rates for these subgroups 
in the historical control group (72% [95% CI, 
68 to 75] in patients with HCV genotype 1a in-
fection and 80% [95% CI, 75 to 84] in those with 
HCV genotype 1b infection).12 If the lower bound-
ary of the 95% confidence interval for the rate of 
sustained virologic response at post-treatment 
week 12 exceeded 75% among patients with HCV 
genotype 1a infection or 84% among those with 
HCV genotype 1b infection, the rate with the 
active regimen was considered to be superior to 
the historical control rate in that subgroup. 
Details of the noninferiority and superiority 
analyses and sample-size determination are pro-
vided in the Supplementary Appendix. A fixed-
sequence testing procedure was used to main-
tain the type I error rate at a level of 0.05 as the 
primary and secondary efficacy end points were 
analyzed in a specific order (see the Supple men-
tary Appendix).
SAS software, version 9.3, for the UNIX oper-
ating system (SAS Institute) was used for all 
analyses. All statistical tests and 95% confidence 
intervals were two-sided, with a significance 
level of 0.05. Differences in baseline characteris-
tics between the treatment groups were evalu-
ated with the use of the chi-square test for cate-
gorical data and one-way analysis of variance for 
continuous data. Comparisons of rates of nor-
malization of the alanine aminotransferase level, 
adverse events, and laboratory abnormalities were 
performed with the use of Fisher’s exact test.
The relationship between prespecified base-
line characteristics (e.g., fibrosis score) and the 
rate of sustained virologic response at post-
treatment week 12 was analyzed by means of 
stepwise logistic regression to determine inde-
pendent predictors of sustained virologic re-
sponse at post-treatment week 12. The fibrosis 
score (on a scale from F0, indicating no fibrosis, 
to F4, indicating cirrhosis) was determined by 
means of liver biopsy (Metavir, Batts–Ludwig, 
Knodell, International Association for the Study 
of the Liver, Scheuer, Laennec, or Ishak scor-
ing system), FibroTest, or FibroScan (Echosens). 
Additional details of the stepwise logistic- 
regression analysis and fibrosis scoring are pro-
vided in Table S2 in the Supplementary Ap-
pendix.
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R ESULT S
PATIENTS
A total of 855 patients were screened, 636 under-
went randomization, and 631 (473 patients in 
group A and 158 in group B) received at least one 
dose of study drug (Fig. S1 in the Supplementary 
Appendix). The final date for the collection of 
data to be used in the analysis of the rate of sus-
tained virologic response at post-treatment week 
12 was November 4, 2013. The characteristics of 
the patients at baseline are shown in Table 1.
EFFICACY
By week 4 of the double-blind treatment period, 
the HCV RNA level was below 25 IU per milli-
liter in 99.4% of the patients who were receiving 
the active regimen (461 of the 464 patients in 
group A with data available) (Fig. S2 in the Sup-
plementary Appendix). In the modified intention-
to-treat analysis, the rate of sustained virologic 
response at post-treatment week 12 was 96.2% 
(95% CI, 94.5 to 97.9) in group A (455 of 473 pa-
tients) (Fig. 2). This rate was noninferior and supe-
rior to the historical control rate with telaprevir 
plus peginterferon–ribavirin.
The rate of sustained virologic response at 
post-treatment week 12 was 95.3% (95% CI, 93.0 
to 97.6) among patients with HCV genotype 1a 
infection (307 of 322 patients) and 98.0% (95% 
CI, 95.8 to 100) among those with HCV geno-
type 1b infection (148 of 151). These rates were 
superior to the historical control rates in the 
respective subgroups (Fig. 2).
Figure 3 shows the rates of sustained viro-
logic response at post-treatment week 12 in ad-
ditional patient subgroups. The rates were simi-
larly high in all subgroups, including those 
defined by IL28B genotype (96.5% with CC and 
96.0% with non-CC), race (96.4% among black 
patients and 96.2% among nonblack patients), 
fibrosis score at baseline (97.0% with a score of 
F0 or F1, 94.3% with a score of F2, and 92.5% 
with a score of F3), and baseline HCV RNA level 
(98.1% with a level <800,000 IU per milliliter 
and 95.7% with a level ≥800,000 IU per milli-
liter). The rate of sustained virologic response at 
post-treatment week 12 was 93.5% among pa-
tients who had a modification of the ribavirin 
dose (29 of 31 patients) and 96.4% among those 
who did not have a dose modification (426 of 442).
Stepwise logistic-regression analysis showed 
that characteristics including age, sex, race, ethnic 
group, IL28B genotype, fibrosis score, and base-
line viral load did not have a significant effect on 
the sustained virologic response at post-treat-
ment week 12. Only high baseline body-mass 
index (the weight in kilograms divided by the 
square of the height in meters) was associated 
with a reduced rate, although the effect was 
modest (odds ratio, 0.89; P = 0.02); even among 
patients with a body-mass index of 30 or more, 
the rate of sustained virologic response at post-
treatment week 12 was high (91.5%) (Table S4 in 
the Supplementary Appendix).
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic
Group A  
(N = 473)
Group B  
(N = 158)
Male sex — no. (%) 271 (57.3) 73 (46.2)
Race — no. (%)†
White 428 (90.5) 144 (91.1)
Black 26 (5.5) 8 (5.1)
Other 19 (4.0) 6 (3.8)
Hispanic ethnic group — no. (%)† 27 (5.7) 5 (3.2)
Age — yr
Mean 49.4 51.2
Range 18.0–70.0 21.0–70.0
Body-mass index‡
Mean 25.7 26.2
Range 18.0–38.4 18.5–39.4
Fibrosis score ≥F2 — no. (%)§ 110 (23.3) 42 (26.6)
IL28B CC genotype — no. (%) 144 (30.4) 50 (31.6)
HCV genotype — no. (%)
1a 322 (68.1) 105 (66.5)
1b 151 (31.9) 53 (33.5)
HCV RNA — log10 IU/ml 6.40±0.62 6.47±0.65
* Plus–minus values are means ±SD. Group A received the active regimen of 
ABT-450 with ritonavir (ABT-450/r)–ombitasvir and dasabuvir with ribavirin, 
and group B matching placebos. Differences in baseline characteristics be-
tween the treatment groups were evaluated with the use of the chi-square test 
for categorical data and one-way analysis of variance for continuous data. 
There were no significant between-group differences, except for sex (P = 0.02). 
HCV denotes hepatitis C virus.
† Race and ethnic group were self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
§ The fibrosis score was determined by means of liver biopsy (and was scored 
with the use of the Metavir, Batts–Ludwig, Knodell, International Association 
for the Study of the Liver, Scheuer, Laennec, or Ishak scoring system) or with 
the use of FibroScan (Echosens) or FibroTest. Scores range from F0 (no fibro-
sis) to F4 (cirrhosis). Details regarding scoring are provided in Table S2 in the 
Supplementary Appendix.
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Patients in group A took an average of 98.9% 
or more of their prescribed doses of each pill. 
The rate of normalization of the alanine amino-
transferase level was 97.0% in group A (352 of 
363 patients), as compared with 14.9% in group B 
(17 of 114) (P<0.001).
VIROLOGIC FAILURE during treatment  
AND RELAPSE
Among the 473 patients in group A, 1 patient 
(0.2%) had virologic failure during the double-
blind treatment period. In this HCV genotype 1a–
infected patient who had adhered to the treat-
ment regimen, the HCV RNA level became 
quantifiable at treatment week 12. A total of 7 of 
463 patients (1.5%) had a relapse by post-treat-
ment week 12, of whom 5 had a relapse at or 
before the visit at post-treatment week 4.
Each of the eight patients who had virologic 
failure during treatment or relapse had at least 
one amino acid variant that was known to con-
fer resistance to one of the three direct-acting 
antiviral agents included in the regimen. The 
most frequently detected variants in the seven 
patients with HCV genotype 1a infection at the 
time of virologic failure during treatment or re-
lapse were D168V (in six patients) in the protein 
NS3, M28T (in two) and Q30R (in three) in the 
protein NS5A, and S556G (in three) in the pro-
tein NS5B. The single patient with HCV genotype 
1b infection who had relapse had variants Y56H 
and D168V in the protein NS3, L31M and Y93H 
in the protein NS5A, and S556G in the protein 
NS5B at the time of relapse.
SAFETY
During the double-blind period, 87.5% of the pa-
tients who were receiving the active regimen 
(group A), as compared with 73.4% of those re-
ceiving placebo (group B), had an adverse event 
(P<0.001) (Table 2). Events were mild in most 
patients. The most common adverse events were 
fatigue (in 34.7% of the patients in group A and 
28.5% of those in group B) and headache (in 
33.0% of the patients in group A and 26.6% of 
those in group B); the frequency of these events 
did not differ significantly between the study 
groups (P>0.05 for both comparisons). Among 
adverse events that occurred in more than 10% of 
patients in either group, five occurred in signifi-
cantly more patients in group A than in group B: 
nausea (23.7% vs. 13.3%), pruritus (16.9% vs. 
3.8%), insomnia (14.0% vs. 7.6%), diarrhea 
(13.7% vs. 7.0%), and asthenia (12.1% vs. 3.8%) 
(P<0.05 for each comparison).
Discontinuation due to an adverse event oc-
curred in 0.6% of the patients in each group 
(3 patients in group A and 1 in group B). Of 
the 3 patients in group A who discontinued owing 
to an adverse event, 2 did not have a sustained 
virologic response at post-treatment week 12, 
and 1, a patient who discontinued the study drug 
during week 11, had a sustained virologic re-
sponse at post-treatment week 12. Serious ad-
verse events occurred in 10 patients in group A 
(2.1%) (Table 2, and Table S6 in the Supplementary 
Appendix). No patient in group B had a serious 
adverse event during the double-blind period.
Clinically significant chemical and hemato-
logic abnormalities of grade 3 and 4 that oc-
curred during the double-blind period are shown 
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Figure 2. Rates of Sustained Virologic Response among All Patients and 
According to HCV Genotype in the Historical Control Group and in Group A.
To establish the noninferiority and superiority of ABT-450/r–ombitasvir and 
dasabuvir with ribavirin to the historical control (telaprevir and peginterferon–
ribavirin) in all patients, the lower boundary of the 95% confidence interval 
for the rate of sustained virologic response at post-treatment week 12 among 
patients in group A (patients receiving ABT-450/r–ombitasvir and dasabuvir 
with ribavirin during the double-blind period) had to exceed 70% (for non-
inferiority) and 80% (for superiority). To establish the superiority of the 
active regimen to the historical control in HCV genotype 1a–infected pa-
tients and HCV genotype 1b–infected patients, the lower boundary of the 
95% confidence interval for the rate of sustained virologic response at post-
treatment week 12 among patients in these subgroups in group A had to 
exceed 75% and 84%, respectively. Dots indicate the point estimates in the 
control group. I bars indicate 95% confidence intervals. Numbers above 
the confidence intervals are the rates of sustained virologic response.
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in Table 2. The most frequent chemical abnor-
mality of grade 3 or 4 in group A was a grade 3 
elevated total bilirubin level (in 13 of 469 pa-
tients [2.8%]); no patient had an elevation of 
grade 4. Elevations in the bilirubin level involved 
predominantly indirect bilirubin. In 9 of these 
13 patients, the elevation was observed at a single 
visit. A total of 2 of these 13 patients had clini-
cally recognized jaundice. All elevated bilirubin 
levels improved or resolved without discontinua-
tion of the study drug.
In group A, 4 of 469 patients (0.9%) had an 
elevated alanine aminotransferase level of grade 3 
or 4. In these 4 patients, the alanine aminotrans-
ferase level declined with ongoing treatment 
and was either within the normal range or at 
grade 1 at the first post-treatment visit. One of 
these 4 patients had an associated grade 2 eleva-
70.0 80.0 90.0 96.2 100
Rate of Sustained Virologic Response at Post-Treatment Wk 12 (%)
Sex
Male
Female
Race
Black
Nonblack
Ethnic group
Hispanic
Non-Hispanic
Age
<55 yr
≥55 yr
Body-mass index
<30
≥30
Fibrosis score
F0 or F1
F2
F3
IL28B genotype
CC
Non-CC
History of diabetes
Yes
No
HCV RNA level
<800,000 IU/ml
≥800,000 IU/ml
Ribavirin dose modification
Yes
No
No. of Patients
(NI=I473)
Percent of Patients with Response
(95% CI)
Subgroup
95.2 (92.7–97.8)
96.4 (94.6–98.1)
93.5 (84.9–100.0)
95.7 (93.6–97.7)
98.1 (95.4–100.0)
96.0 (93.9–98.2)
96.5 (93.5–99.5)
100.0 (100.0–100.0)
96.0 (94.2–97.8)
94.3 (88.9–99.7)
92.5 (84.3–100.0)
97.0 (95.2–98.7)
91.5 (85.1–98.0)
97.0 (95.4–98.7)
95.6 (92.7–98.6)
96.6 (94.5–98.7)
96.4 (94.7–98.1)
92.6 (82.7–100.0)
96.2 (94.4–98.0)
96.4 (89.6–100.0)
0.0 60.0
97.5 (95.4–99.7)
271
202
28
445
27
446
290
183
402
71
363
70
40
144
329
19
454
104
369
31
442
Figure 3. Rates of Sustained Virologic Response at Post-Treatment Week 12 in Group A, According to Subgroup  
and Baseline Variables.
The position of the circle indicates the rate of sustained virologic response at post-treatment week 12; the bars are 
95% confidence intervals. The dotted vertical line indicates the overall rate of sustained virologic response at post-
treatment week 12 in group A. Race and ethnic group were self-reported. The body-mass index is the weight in kilo-
grams divided by the square of the height in meters. The fibrosis score ranges from F0 (no fibrosis) to F4 (cirrhosis). 
No patient had a fibrosis score of F4. The 31 patients with a reduction in the ribavirin dose included 26 who had the 
dose modified owing to adverse events and 5 who had the dose modified for other reasons (e.g., weight change). 
The rates in additional patient subgroups are provided in Table S3 in the Supplementary Appendix.
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tion in the total bilirubin level (predominantly 
indirect bilirubin), which declined to within the 
normal range at the first post-treatment visit. All 
these patients had a sustained virologic response 
at post-treatment week 12.
Grade 1 reductions in the hemoglobin level 
(ranging from below the lower limit of the nor-
mal range to 10.0 g per deciliter) occurred in 
47.5% of patients in group A and 2.5% of those 
in group B. Grade 2 reductions (<10.0 to 8.0 g 
per deciliter) occurred in 5.8% of patients in 
group A and in no patients in group B. There 
were no hemoglobin reductions of grade 3 or 4 
(<8.0 g per deciliter) in either study group (Table 
S7 in the Supplementary Appendix). The ribavi-
rin dose was modified owing to adverse events 
in 5.5% of the patients in group A. No patient 
discontinued the study treatment owing to ane-
mia. One patient received erythropoietin. No 
patient received a transfusion.
DISCUSSION
This large, international, phase 3 trial showed 
the efficacy of an interferon-free, all-oral antivi-
ral therapy for previously untreated patients with 
HCV genotype 1 infection and no cirrhosis. In 
the modified intention-to-treat analysis, the rate 
of sustained virologic response at post-treatment 
week 12 among patients who received 12 weeks 
of ABT-450/r–ombitasvir and dasabuvir with rib-
avirin was 96.2%, a rate that was noninferior and 
superior to the historical control rate with telapre-
vir and peginterferon–ribavirin. This multitargeted 
regimen resulted in a low rate of virologic failure 
(virologic failure occurred during treatment in 0.2% 
of the patients, and relapse after the end of treat-
ment in 1.5%), which limited the number of pa-
tients in whom drug resistance developed.
The rate of sustained virologic response at 
post-treatment week 12 observed in our study 
compares favorably with the rates of 67 to 89% 
reported in phase 3 trials involving previously 
untreated patients with HCV genotype 1 infec-
tion who received peginterferon and ribavirin 
with a direct-acting antiviral agent, such as tela-
previr, boceprevir, simeprevir, or sofosbuvir.3,4,6,7 
Findings from small, phase 2 studies suggest 
that peginterferon-free regimens of direct-acting 
antiviral agents with or without ribavirin may be 
associated with high rates of sustained virologic 
Table 2. Adverse Events and Chemical and Hematologic Abnormalities  
of Grade 3 or 4 during the Double-Blind Treatment Period.*
Event
Group A 
(N = 473)
Group B 
(N = 158)
Any adverse event — no. of patients (%) 414 (87.5)† 116 (73.4)
Any adverse event leading to discontinuation of 
study drug — no. of patients (%)‡
3 (0.6) 1 (0.6)
Any serious adverse event — no. of patients (%)§ 10 (2.1) 0
Common adverse event — no. of patients (%)
Fatigue 164 (34.7) 45 (28.5)
Headache 156 (33.0) 42 (26.6)
Nausea 112 (23.7)† 21 (13.3)
Pruritus 80 (16.9)† 6 (3.8)
Insomnia 66 (14.0)† 12 (7.6)
Diarrhea 65 (13.7)† 11 (7.0)
Asthenia 57 (12.1)† 6 (3.8)
Rash 51 (10.8) 9 (5.7)
Grade 3 or 4 chemical or hematologic abnor-
mality — no. of patients/total no. (%)¶
Alanine aminotransferase 4/469 (0.9) 7/158 (4.4)†
Aspartate aminotransferase 3/469 (0.6) 3/158 (1.9)
Alkaline phosphatase 0 0
Total bilirubin‖ 13/469 (2.8)† 0
Hemoglobin 0 0
* The common adverse events listed here are events that occurred in more than 10% 
of patients in either group during treatment. Events occurring in more than 5% 
of patients of any group are shown in Table S5 in the Supplementary Appendix.
† P<0.05.
‡ Adverse events leading to treatment discontinuation in group A were lobar 
pneumonia in one patient, acute respiratory failure and hypoxemia in one, and 
abdominal pain, sinus tachycardia, diarrhea, chills, vomiting, nausea, and 
ventricular extrasystoles in one. In group B, syncope led to treatment discon-
tinuation in one patient.
§ Serious adverse events were appendicitis, lobar pneumonia, cholecystitis, and 
lumbar vertebral fracture (caused by a vehicle accident), occurring in one pa-
tient each; aortic stenosis and postoperative wound infection in one; overdose 
and encephalopathy in one; mediastinal mass and non–small-cell lung cancer 
in one; acute respiratory failure and hypoxemia in one; abdominal pain,  sinus 
tachy cardia, diarrhea, chills, vomiting, nausea, and ventricular extrasystoles 
in one; and anemia and noncardiac chest pain in one.
¶ Data on alanine aminotransferase, aspartate aminotransferase, alkaline phos-
phatase, total bilirubin, and hemoglobin levels were missing for four patients 
in group A. An aminotransferase (alanine or aspartate) level of grade 3 was de-
fined as a level that was more than 5 to 20 times the upper limit of the normal 
range, and grade 4 as a level that was more than 20 times the upper limit of the 
normal range. An alkaline phosphatase level of grade 3 was defined as a level 
that was more than 5 to 20 times the upper limit of the normal range, and 
grade 4 as a level that was more than 20 times the upper limit of the normal 
range. A total bilirubin level of grade 3 was defined as a level that was more 
than 3 to 10 times the upper limit of the normal range, and grade 4 as a level 
that was more than 10 times the upper limit of the normal range. A hemoglobin 
level of grade 3 was defined as a level that was less than 8.0 to 6.5 g per deci-
liter, and grade 4 as a level that was less than 6.5 g per deciliter. The numbers of 
patients with a reduced hemoglobin level of grade 1 or 2 are provided in Table S7 
in the Supplementary Appendix.
‖ Total bilirubin was predominantly indirect bilirubin.
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response at post-treatment week 12.9,11,13-17 The 
rate observed here is consistent with results of a 
phase 2b trial in which treatment for 12 weeks 
with ABT-450/r, ombitasvir, dasabuvir, and riba-
virin was associated with a sustained virologic 
response at post-treatment week 24 in 96% of 
previously untreated patients with HCV geno-
type 1 infection.11
The efficacy of different treatment regimens 
with antiviral agents may vary according to HCV 
genotype (1a or 1b).6,7,9,18 In this trial, the rates 
of sustained virologic response at post-treatment 
week 12 were similar among patients with HCV 
genotype 1a infection and those with HCV geno-
type 1b infection (95.3% and 98.0%, respectively). 
Previous reports have indicated reduced response 
rates with peginterferon-containing therapies 
among patients with certain characteristics, in-
cluding IL28B non-CC genotype, black race, and 
high viral load.3,4 In this trial, the rates were 
high across these subgroups.
The double-blind, placebo-controlled study de-
sign allowed the comparison of adverse events 
between patients receiving the active regimen 
and those receiving placebo. Fatigue and head-
ache were the most common adverse events, but 
their frequency did not differ significantly be-
tween the study groups. The most common ad-
verse events that occurred significantly more 
frequently among patients receiving the active 
regimen were nausea, pruritus, insomnia, diar-
rhea, and asthenia. The rate of discontinuation due 
to adverse events was 0.6% in each study group. 
The rate of serious adverse events was low, with 
such events occurring in 2.1% of the patients 
who received the active regimen (10 patients).
The adverse-event profile for the active regimen 
compares favorably with that for a protease in-
hibitor plus peginterferon–ribavirin. Rates of 9 to 
12% for serious adverse events and rates of 10 to 
16% for discontinuation due to adverse events 
have been reported among previously untreated 
patients receiving telaprevir or boceprevir with 
peginterferon–ribavirin.3,4 Clinically significant 
anemia leading to erythropoietin use, reduction 
of the ribavirin dose, and occasionally blood 
transfusions have also been reported.19 In our 
study, among patients receiving the active regi-
men during the double-blind period, reductions 
in the hemoglobin level of grade 1 were common 
(in 47.5% of patients), hemoglobin reductions of 
grade 2 were uncommon (in 5.8%), and there 
were no hemoglobin reductions of grade 3 or 4.
Modifications of the ribavirin dose due to ad-
verse events were relatively uncommon (in 26 pa-
tients [5.5%]), and no patient discontinued the 
study drug owing to anemia. An elevated total 
bilirubin level was the most frequent laboratory 
abnormality of grade 3 or 4. The elevations were 
typically transient and were infrequently associat-
ed with jaundice. The elevations in the bilirubin 
level involved predominantly indirect bilirubin 
and were consistent with the known inhibitory 
effect of ABT-450 on the bilirubin transporters 
OATP1B1 and OATP1B320,21 and the known role 
of ribavirin in hemolysis.
We excluded from our trial patients with cir-
rhosis and patients who were using medications 
contraindicated with ritonavir and ribavirin. 
Although this study did not include patients who 
had received prior treatment, Zeuzem et al. now 
report in the Journal that a study evaluating the 
same active regimen in patients who had received 
prior treatment with peginterferon–ribavirin has 
shown high rates of sustained virologic response 
at post-treatment week 12.22
In conclusion, a multitargeted approach com-
bining the direct-acting antiviral agents ABT-
450/r–ombitasvir and dasabuvir with ribavirin was 
associated with a high rate of sustained viro-
logic response at post-treatment week 12, with a 
low rate of treatment discontinuation, among 
previously untreated patients with HCV geno-
type 1 infection and no cirrhosis.
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